Oncolytics Biotech Inc. (NASDAQ:ONCY – Get Rating) was the recipient of a significant growth in short interest in April. As of April 15th, there was short interest totalling 233,400 shares, a growth of 53.7% from the March 31st total of 151,900 shares. Based on an average daily volume of 259,700 shares, the days-to-cover ratio is currently 0.9 days.
Shares of Oncolytics Biotech stock opened at $1.32 on Friday. Oncolytics Biotech has a 52 week low of $1.25 and a 52 week high of $3.21. The business’s fifty day simple moving average is $1.54 and its 200-day simple moving average is $1.70. The firm has a market cap of $75.39 million, a PE ratio of -3.38 and a beta of 2.33.
Oncolytics Biotech (NASDAQ:ONCY – Get Rating) last announced its quarterly earnings results on Thursday, March 3rd. The company reported ($0.11) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.03. On average, research analysts expect that Oncolytics Biotech will post -0.47 earnings per share for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of ONCY. LPL Financial LLC lifted its stake in Oncolytics Biotech by 71.3% during the 3rd quarter. LPL Financial LLC now owns 20,489 shares of the company’s stock worth $43,000 after acquiring an additional 8,529 shares in the last quarter. Long Focus Capital Management LLC acquired a new position in Oncolytics Biotech during the 4th quarter worth about $56,000. UBS Group AG increased its holdings in Oncolytics Biotech by 29.5% during the 3rd quarter. UBS Group AG now owns 26,790 shares of the company’s stock worth $56,000 after purchasing an additional 6,101 shares during the period. Dimensional Fund Advisors LP purchased a new stake in Oncolytics Biotech during the 3rd quarter worth about $70,000. Finally, Geode Capital Management LLC increased its holdings in Oncolytics Biotech by 41.2% during the 3rd quarter. Geode Capital Management LLC now owns 34,659 shares of the company’s stock worth $72,000 after purchasing an additional 10,114 shares during the period. 1.87% of the stock is currently owned by hedge funds and other institutional investors.
About Oncolytics Biotech (Get Rating)
Oncolytics Biotech Inc, a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies.
- Get a free copy of the StockNews.com research report on Oncolytics Biotech (ONCY)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.